← Back

Shanghai Kaibao Pharmaceutical

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases. Further, it offers diclofenac sodium enteric-coated tablets; artificial bezoar metronidazole capsules; Mai'an granules; Loquat cough granules that clears the lungs, relieves cough, and reduces phlegm; compound danshen tablets; Tongmai granules to promote blood circulation and unblocks meridians; pediatric pharyngeal granules; stroke rejuvenation pills; and Xiao Chai Hu granules which relieves exterior syndromes, clears heat, soothes the liver, and harmonizes the stomach. Further, the company provides Alopecia areata; Bear bile drops that clears heat, calms the liver, and improves eyesight, as well as used for infantile convulsions and sore throat; and Shanhaidan capsules. Shanghai Kaibao Pharmaceutical CO.,Ltd was founded in 2000 and is based in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 300039.CS
300039.CS▼3

Shanghai Kaibao first-half 2026 net profit 102 million yuan, down 16.42% year on year

Shanghai Kaibao disclosed its 2026 semi-annual report. In the first half, total operating revenue was 463 million yuan, down 23.44% year on year. Net profit attributable to the parent company was 102 million yuan, down 16.42% year on year. Net profit after deducting non-recurring items was 96.9969 million yuan, down 17.37% year on year. Net cash flow from operating activities was 109 million yuan, down 31.92% year on year. Basic earnings per share were 0.0975 yuan, and the weighted average return on equity was 2.32%. Based on the closing price on August 24, the company's price-to-earnings ratio on a trailing twelve-month basis was about 21.4 times, the price-to-book ratio on a latest fiscal year basis was about 1.29 times, and the price-to-sales ratio on a trailing twelve-month basis was about 5.47 times.
300039.CS ▼
中国证券报·2dRead more ▾
300039.CS▲

State Council Approves Traditional Chinese Medicine 15th Five-Year Plan, Igniting TCM Sector; Longshen Rongfa Hits 20% Daily Limit Up

The State Council has approved in principle the Traditional Chinese Medicine Revitalization and Development 15th Five-Year Plan, igniting the TCM sector. On July 13, Longshen Rongfa hit the 20 percent daily limit up, Shanghai Kaibao and Biotech Valley surged over 10 percent, Tianmu Pharmaceutical hit the daily limit up, and many other stocks rose in sympathy. CITIC Securities believes that the cliff-like drop in upstream precious medicinal material prices has shed the cost burden, the midstream destocking cycle is nearing its end, and cost savings will flow through to the income statement. The current moment is the optimal window for contrarian positioning in the profit recovery inflection point of the TCM OTC sector. China Post Securities noted that branded TCM companies have stable cash flows, and high-dividend TCM firms are trading at historically reasonable or low valuations, offering allocation appeal in a low-interest-rate environment. It suggests paying attention to names such as Dong-E-E-Jiao, Jumpcan Pharmaceutical, and China Resources Jiangzhong.
300534.CS ▲000423.CS ▲600566.CG ▲600750.CG ▲300039.CS ▲600671.CG ▲
21世纪经济·45dRead more ▾
© 2026 MarketDXAsset